Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it had a pre-investigational new drug application (PIND) meeting with the U.S. Food and Drug A

By: financialpost.com

Feb 27 2024
81
5152 Views

Arch has the opportunity to sponsor a Phase II trial for cilastatin in toxin-related AKI targeting either nephrotoxic drug and/or rhabdomyolysis-associated AKI (explained further below). Read More

Township of Black River-Matheson and CUPE 1490 Reach Tentative Agreement and Return to Work Protocol

Kolibri Global Energy Inc. Revocation of Management Cease Trade Order

Anaergia Announces Additional Delay in the Filing of Its Audited Financial Statements and Related Disclosures

Boeing threatens to lock out its private firefighters around Seattle in a dispute over pay

Slate Office REIT Announces Voting Results from 2024 Meeting of Unitholders and Posts Q1 2024 Earnings Call Transcript and Investor Update

Galway Metals Announces Second Closing of Private Placement of Flow-Through Units

Ultra Lithium Provides Bi-Weekly Default Status Report

BetterLife Announces Intent to Complete Private Placement of Units

Safety lapses contributed to patient assaults at Oregon State Hospital, federal report says

Most actively traded companies on the Toronto Stock Exchange

AGF Reports April 2024 Assets Under Management and Fee-Earning Assets

Global Helium Corp. Grants Stock Options

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches